February: Petrovax Pharm signs a trilateral strategic cooperation agreement in order to localize production of the Russian flu vaccine Grippol^® Plus in Iran.

Petrovax Pharm launches Imoferaza^®, an innovative ointment to treat problem areas and scar tissue after injuries, burns, acne, surgeries, and cosmetic procedures.

June: Petrovax Pharm and the German firm Boehringer Ingelheim sign an agreement to localize in Russia the full production cycle of state-of-the-art medicines for cardiovascular diseases.

July: Petrovax Pharm receives a Russian GMP compliance certificate following a directive of the Russian Federation Ministry of Industry and Trade.

August: Petrovax Pharm exports 1.5 million doses of Grippol^® Plus flu vaccine to Kazakhstan.

October: Petrovax Pharm supplies more than 8.5 million doses of pediatric Grippol^® Plus flu vaccine to meet the National Vaccination Schedule of the Russian Federation.

Polyoxidoniy, manufactured by Petrovax Pharm, receives a 2016 Russian Pharma Award for best pediatric immunity booster for acute upper respiratory infections.

Petrovax Pharm supplies 1.5 million doses of Grippol^® Plus to Kazakhstan under the national drug and medical supplies procurement program.

At the beginning of the year NPO Petrovax Pharm invested over 900 million rubles in a new production line that meets all GMP requirements, allowing a two-and-a-half-fold increase in the production of pharmaceutical substances, a seven-fold increase in the production of pills, and a quadrupling of its suppositories production capacity.

In March, NPO Petrovax Pharm was again certified by the Ministry of Industry and Trade as having a manufacturing and management systems compliant with the GMP quality requirements, thus confirming that the company meets their high standards. Soon after, Petrovax Pharm announced an extension of the recommended age group for the use of Polyoxidonium ^® to include children starting at 3 years old.

In June, under the sponsorship of NPO Petrovax Pharm and the Interros Group, the country-wide scientific forum «Days of Immunology in Saint Petersburg» held its sixteenth session in Saint-Petersburg.

In July, the company received a report on the successful conclusion of the EU post-authorization safety study (PASS) for Polyoxidonium ^® in injections. The study confirmed its high tolerability and safety profile in patients.

In August, NPO Petrovax Pharm began exporting more than 2 million doses of the Grippol Plus ^® flu vaccine to Kazakhstan. In October, a wide-spread free immunization campaign began in Belarus, for which the government procured Grippol Plus ^® vaccine from NPO Petrovax Pharm.

In the middle of October the first batches of Metalize ^®, a drug to treat acute myocardial infarction, became available to patients in Russia. Production was localized in Russia in partnership with Boehringer Ingelheim. At the end of the month, Petrovax Pharm received an ISO 9001:2015 management quality control system compliance certificate. In addition to the main ISO 9001:2015 certificate, Petrovax also obtained an IQNet single international certificate.

At the end of the year, the company donated 200 thousand doses of Grippol Plus^® vaccine to clinics in the Moscow region to prevent flu epidemic.

Polyoxidonium ^® won Russian Pharma Awards 2017, an annual competition held for the 6th time, in the «Drug of Choice to Prevent and Treat Acute Respiratory Infection and Flu in Children» category.

In February 2018, NPO Petrovax Pharm received an award for «Dynamic Business Development» from the Russian Union of Industrialists and Entrepreneurs. The same month, Boehringer Ingelheim and Petrovax Pharm completed another phase in the process to begin domestic production of advanced thrombolytic drugs in Russia. The first supplies of Aktilise^® for treatment of ischemic strokes have been delivered to Russian clinics.

In May 2018, Polyoxidonium won the Smartpharma Awards 2018. It received more votes than any other product in the category «Recommendation of the Year for Treatment of Acute Respiratory Infection and Flu in Children 3 years and older», putting it in first place.

In July, NPO Petrovax Pharm obtained a registration certificate to sell Grippol^®Quadrivalent, the first quadrivalent influenza vaccine in Russia. This is the most advanced of the existing flu vaccines in the world, both highly effective and safe. The vaccine offers protection from four strains of influenza.

In September, NPO Petrovax pharmaceutical complex produced the first batch of preservatives-free, single-use Grippol^®Quadrivalent vaccine syringes in accordance with the GMP standards, and thus marked the company’s tenth anniversary. Petrovax also launched the third production line for the manufacture of pills, suppositories and substances.

In November, Petrovax Pharm won PRIORITY-2018, the national award on import substitution, for the company’s contribution towards the creation and introduction of the Grippol^®Quadrivalent vaccine into wide-spread healthcare practice in Russia. The very same month, at the Russian Pharma Awards, the VII national pharmaceutical award event, doctors voted for NPO Petrovax Pharm’s two products — Polyoxidonium^® and Longidaza^® — as the best medicines.